-
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials Lancet (IF 168.9) Pub Date : 2023-11-23 Marcus Maurer, Luis Felipe Ensina, Ana Maria Gimenez-Arnau, Gordon Sussman, Michihiro Hide, Sarbjit Saini, Clive Grattan, Daria Fomina, Dimitrios Rigopoulos, Frederic Berard, Giorgio Walter Canonica, Heike Rockmann, Carla Irani, Jacek C Szepietowski, Jeffrey Leflein, Jonathan A Bernstein, Jonny G Peter, Kanokvalai Kulthanan, Kiran Godse, Ledit Ardusso, Zook Matthew
Background Many patients with chronic spontaneous urticaria (CSU) do not achieve complete control of their symptoms with current available treatments. In a dose-finding phase 2b study, ligelizumab improved urticaria symptoms in patients with H1-antihistamine (H1-AH) refractory CSU. Here, we report the efficacy and safety outcomes from two ligelizumab phase 3 studies. Methods PEARL-1 and PEARL-2 were
-
Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial Lancet (IF 168.9) Pub Date : 2023-11-15 Kamala Thriemer, Tamiru Shibiru Degaga, Michael Christian, Mohammad Shafiul Alam, Megha Rajasekhar, Benedikt Ley, Mohammad Sharif Hossain, Mohammad Golam Kibria, Tedla Teferi Tego, Dagamawie Tadesse Abate, Sophie Weston, Hellen Mnjala, Angela Rumaseb, Ari Winasti Satyagraha, Arkasha Sadhewa, Lydia Vista Panggalo, Lenny L Ekawati, Grant Lee, Rodas Temesgen Anose, Fitsum Getahun Kiros, Ric N Price
Background In areas co-endemic for Plasmodium vivax and Plasmodium falciparum there is an increased risk of P vivax parasitaemia following P falciparum malaria. Radical cure is currently only recommended for patients presenting with P vivax malaria. Expanding the indication for radical cure to patients presenting with P falciparum malaria could reduce their risk of subsequent P vivax parasitaemia.
-
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA Lancet (IF 168.9) Pub Date : 2023-11-15 David W Dodick, Peter J Goadsby, Todd J Schwedt, Richard B Lipton, Chengcheng Liu, Kaifeng Lu, Sung Yun Yu, Lawrence Severt, Michelle Finnegan, Joel M Trugman
Background Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that is approved for acute treatment of migraine. The prodrome is the earliest phase of a migraine attack and is characterised by non-aura symptoms that precede headache onset. The aim of this trial was to evaluate the efficacy, safety, and tolerability of ubrogepant 100 mg compared with placebo for the acute treatment
-
Deferred cord clamping, cord milking, and immediate cord clamping at preterm birth: a systematic review and individual participant data meta-analysis Lancet (IF 168.9) Pub Date : 2023-11-14 Anna Lene Seidler, Mason Aberoumand, Kylie E Hunter, Angie Barba, Sol Libesman, Jonathan G Williams, Nipun Shrestha, Jannik Aagerup, James X Sotiropoulos, Alan A Montgomery, Gillian M L Gyte, Lelia Duley, Lisa M Askie
Background Umbilical cord clamping strategies at preterm birth have the potential to affect important health outcomes. The aim of this study was to compare the effectiveness of deferred cord clamping, umbilical cord milking, and immediate cord clamping in reducing neonatal mortality and morbidity at preterm birth. Methods We conducted a systematic review and individual participant data meta-analysis
-
Treatment of severe symptomatic aortic valve stenosis using non-invasive ultrasound therapy: a cohort study Lancet (IF 168.9) Pub Date : 2023-11-14 Emmanuel Messas, Alexander Ijsselmuiden, Danijela Trifunović-Zamaklar, Bernard Cholley, Etienne Puymirat, Jonathan Halim, Radmila Karan, Menno van Gameren, Duško Terzić, Vladimir Milićević, Mickael Tanter, Mathieu Pernot, Guillaume Goudot
Background Calcific aortic stenosis is commonly treated using surgical or transcatheter aortic valve replacement; however, many patients are not considered suitable candidates for these interventions due to severe comorbidities and limited life expectancy. As such, non-invasive therapies might offer alternative therapeutic possibilities in these patients. This study aimed to assess the safety of non-invasive
-
Short, medium, and long deferral of umbilical cord clamping compared with umbilical cord milking and immediate clamping at preterm birth: a systematic review and network meta-analysis with individual participant data Lancet (IF 168.9) Pub Date : 2023-11-14 Anna Lene Seidler, Sol Libesman, Kylie E Hunter, Angie Barba, Mason Aberoumand, Jonathan G Williams, Nipun Shrestha, Jannik Aagerup, James X Sotiropoulos, Alan A Montgomery, Gillian M L Gyte, Lelia Duley, Lisa M Askie
Background Deferred (also known as delayed) cord clamping can improve survival of infants born preterm (before 37 weeks of gestation), but the optimal duration of deferral remains unclear. We conducted a systematic review and individual participant data network meta-analysis with the aim of comparing the effectiveness of umbilical cord clamping strategies with different timings of clamping or with
-
Impact of discontinuing oxytocin in active labour on neonatal morbidity: an open-label, multicentre, randomised trial Lancet (IF 168.9) Pub Date : 2023-11-09 Aude Girault, Loïc Sentilhes, Raoul Desbrière, Paul Berveiller, Diane Korb, Charline Bertholdt, Julie Carrara, Norbert Winer, Eric Verspyck, Eric Boudier, Tiphaine Barjat, Gilles Levy, Georges Emmanuel Roth, Gilles Kayem, Mona Massoud, Caroline Bohec, Paul Guerby, Elie Azria, Julie Blanc, Hélène Heckenroth, Camille Le Ray
Background Oxytocin is effective in reducing labour duration but can be associated with fetal and maternal complications that could potentially be reduced by discontinuing the treatment during labour. We aimed to assess the impact of discontinuing oxytocin during active labour on neonatal morbidity. Methods STOPOXY was a multicentre, randomised, open-label, controlled, superiority trial conducted in
-
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial Lancet (IF 168.9) Pub Date : 2023-11-03 Quincy Chu, Francesco Perrone, Laurent Greillier, Wei Tu, Maria Carmela Piccirillo, Federica Grosso, Giuseppe Lo Russo, Marie Florescu, Manlio Mencoboni, Alessandro Morabito, Fabiana Letizia Cecere, Giovanni Luca Ceresoli, David E Dawe, Paolo Andrea Zucali, Maria Pagano, John R Goffin, Myriam Locatelli Sanchez, Cesare Gridelli, Gerard Zalcman, Xavier Quantin, Lesley Seymour
Background Pleural mesothelioma usually presents at an advanced, incurable stage. Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the addition of pembrolizumab to platinum–pemetrexed would improve overall survival in patients with pleural mesothelioma. Methods We did this open-label, international, randomised phase 3 trial at 51 hospitals in Canada, Italy, and France
-
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial Lancet (IF 168.9) Pub Date : 2023-11-03 Brad H Rovin, Jonathan Barratt, Hiddo J L Heerspink, Charles E Alpers, Stewart Bieler, Dong-Wan Chae, Ulysses A Diva, Jürgen Floege, Loreto Gesualdo, Jula K Inrig, Donald E Kohan, Radko Komers, Laura Ann Kooienga, Richard Lafayette, Bart Maes, Robert Małecki, Alex Mercer, Irene L Noronha, Se Won Oh, Chen Au Peh, Carlotta Federica Zizzi
Background Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT trial's previously reported interim analysis. Here, we report kidney function and outcomes
-
Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials Lancet (IF 168.9) Pub Date : 2023-11-03
Background Radiotherapy has become much better targeted since the 1980s, improving both safety and efficacy. In breast cancer, radiotherapy to regional lymph nodes aims to reduce risks of recurrence and death. Its effects have been studied in randomised trials, some before the 1980s and some after. We aimed to assess the effects of regional node radiotherapy in these two eras. Methods In this meta-analysis
-
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial Lancet (IF 168.9) Pub Date : 2023-11-03 Hiddo J L Heerspink, Arihiro Kiyosue, David C Wheeler, Min Lin, Emma Wijkmark, Glenn Carlson, Anne-Kristina Mercier, Magnus Åstrand, Sebastian Ueckert, Peter J Greasley, Phil Ambery
Background In patients with chronic kidney disease, SGLT2 inhibitors and endothelin A receptor antagonists (ERAs) can reduce albuminuria and glomerular filtration rate (GFR) decline. We assessed the albuminuria-lowering efficacy and safety of the ERA zibotentan combined with the SGLT2 inhibitor dapagliflozin. Methods ZENITH-CKD was a multicentre, randomised, double-blind, active-controlled clinical
-
Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial Lancet (IF 168.9) Pub Date : 2023-10-25 Juan F Iglesias, Marco Roffi, Sylvain Losdat, Olivier Muller, Sophie Degrauwe, David J Kurz, Laurent Haegeli, Daniel Weilenmann, Christoph Kaiser, Maxime Tapponnier, Stéphane Cook, Florim Cuculi, Dik Heg, Stephan Windecker, Thomas Pilgrim
Background Biodegradable polymer sirolimus-eluting stents improve early stent-related clinical outcomes compared to durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. The long-term advantages of biodegradable polymer sirolimus-eluting stents after complete degradation of its polymer coating
-
Mortality in randomised controlled trials using paclitaxel-coated devices for femoropopliteal interventional procedures: an updated patient-level meta-analysis Lancet (IF 168.9) Pub Date : 2023-10-24 Sahil A Parikh, Peter A Schneider, Christopher M Mullin, Tyson Rogers, William A Gray
Background Numerous randomised clinical trials and real-world studies have supported the safety of paclitaxel-coated devices for the treatment of femoropopliteal occlusive disease. However, a 2018 summary-level meta-analysis suggested an increased mortality risk for paclitaxel-coated devices compared with uncoated control devices. This study presents an updated analysis of deaths using the most complete
-
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial Lancet (IF 168.9) Pub Date : 2023-10-20 Yelena Y Janjigian, Akihito Kawazoe, Yuxian Bai, Jianming Xu, Sara Lonardi, Jean Phillipe Metges, Patricio Yanez, Lucjan S Wyrwicz, Lin Shen, Yuriy Ostapenko, Mehmet Bilici, Hyun Cheol Chung, Kohei Shitara, Shu-Kui Qin, Eric Van Cutsem, Josep Tabernero, Kan Li, Chie-Schin Shih, Pooja Bhagia, Sun Young Rha
Background Evidence for the efficacy of combined PD-1 and HER2 blockade with chemotherapy on progression-free and overall survival in HER2-positive gastro-oesophageal cancer is scarce. The first interim analysis of the randomised, phase 3 KEYNOTE-811 study showed a superior objective response with pembrolizumab compared with placebo when added to trastuzumab plus fluoropyrimidine and platinum-based
-
Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study Lancet (IF 168.9) Pub Date : 2023-10-19 Stefanie N Hinkle, Sunni L Mumford, Katherine L Grantz, Pauline Mendola, James L Mills, Edwina H Yeung, Anna Z Pollack, Sonia M Grandi, Rajeshwari Sundaram, Yan Qiao, Enrique F Schisterman, Cuilin Zhang
Background High weight gain in pregnancy is associated with greater postpartum weight retention, yet long-term implications remain unknown. We aimed to assess whether gestational weight change was associated with mortality more than 50 years later. Methods The Collaborative Perinatal Project (CPP) was a prospective US pregnancy cohort (1959–65). The CPP Mortality Linkage Study linked CPP participants
-
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials Lancet (IF 168.9) Pub Date : 2023-10-19 Jeffrey S Heier, Eleonora M Lad, Frank G Holz, Philip J Rosenfeld, Robyn H Guymer, David Boyer, Federico Grossi, Caroline R Baumal, Jean-Francois Korobelnik, Jason S Slakter, Nadia K Waheed, Ravi Metlapally, Ian Pearce, Nathan Steinle, Anibal A Francone, Allen Hu, David R Lally, Pascal Deschatelets, Cedric Francois, Caleb Bliss, Zora Dubska
Background Geographic atrophy is a leading cause of progressive, irreversible vision loss. The objectives of OAKS and DERBY were to assess the efficacy and safety of pegcetacoplan compared with sham treatment in patients with geographic atrophy. Methods OAKS and DERBY were two 24-month, multicentre, randomised, double-masked, sham-controlled, phase 3 studies, in which patients aged 60 years and older
-
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Lancet (IF 168.9) Pub Date : 2023-10-20 Shukui Qin, Minshan Chen, Ann-Lii Cheng, Ahmed O Kaseb, Masatoshi Kudo, Han Chu Lee, Adam C Yopp, Jian Zhou, Lu Wang, Xiaoyu Wen, Jeong Heo, Won Young Tak, Shinichiro Nakamura, Kazushi Numata, Thomas Uguen, David Hsiehchen, Edward Cha, Stephen P Hack, Qinshu Lian, Ning Ma, David Hsiehchen
Background No adjuvant treatment has been established for patients who remain at high risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We aimed to assess the efficacy of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with high-risk hepatocellular carcinoma. Methods In the global, open-label, phase 3 IMbrave050 study, adult patients
-
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial Lancet (IF 168.9) Pub Date : 2023-10-17 David Russell-Jones, Tetsuya Babazono, Roman Cailleteau, Susanne Engberg, Concetta Irace, Maiken Ina Siegismund Kjaersgaard, Chantal Mathieu, Julio Rosenstock, Vincent Woo, David C Klonoff
Background ONWARDS 6 compared the efficacy and safety of once-weekly subcutaneous insulin icodec (icodec) and once-daily insulin degludec (degludec) in adults with type 1 diabetes. Methods This 52-week (26-week main phase plus a 26-week safety extension), randomised, open-label, treat-to-target, phase 3a trial was done at 99 sites across 12 countries. Adults with type 1 diabetes (glycated haemoglobin
-
Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet (IF 168.9) Pub Date : 2023-10-16 Alexander C Ford, Alexandra Wright-Hughes, Sarah L Alderson, Pei-Loo Ow, Matthew J Ridd, Robbie Foy, Gina Bianco, Felicity L Bishop, Matthew Chaddock, Heather Cook, Deborah Cooper, Catherine Fernandez, Elspeth A Guthrie, Suzanne Hartley, Amy Herbert, Daniel Howdon, Delia P Muir, Taposhi Nath, Sonia Newman, Thomas Smith, Hazel A. Everitt
Background Most patients with irritable bowel syndrome (IBS) are managed in primary care. When first-line therapies for IBS are ineffective, the UK National Institute for Health and Care Excellence guideline suggests considering low- dose tricyclic antidepressants as second-line treatment, but their effectiveness in primary care is unknown, and they are infrequently prescribed in this setting. Methods
-
Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial Lancet (IF 168.9) Pub Date : 2023-10-12 Yuanyuan Wang, Graeme Jones, Helen I Keen, Catherine L Hill, Anita E Wluka, Jessica Kasza, Andrew J Teichtahl, Benny Antony, Richard O'Sullivan, Flavia M Cicuttini
Background Hand osteoarthritis is a disabling condition with few effective therapies. Hand osteoarthritis with synovitis is a common inflammatory phenotype associated with pain. We aimed to examine the efficacy and safety of methotrexate at 6 months in participants with hand osteoarthritis and synovitis. Methods In this multisite, parallel-group, double-blind, randomised, placebo-controlled trial,
-
Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial Lancet (IF 168.9) Pub Date : 2023-10-11 Martin Bendszus, Jens Fiehler, Fabien Subtil, Susanne Bonekamp, Anne Hege Aamodt, Blanca Fuentes, Elke R Gizewski, Michael D Hill, Antonin Krajina, Laurent Pierot, Claus Z Simonsen, Kamil Zeleňák, Rolf A Blauenfeldt, Bastian Cheng, Angélique Denis, Hannes Deutschmann, Franziska Dorn, Fabian Flottmann, Susanne Gellißen, Johannes C Gerber, Seraphine Zubel
Background Recent evidence suggests a beneficial effect of endovascular thrombectomy in acute ischaemic stroke with large infarct; however, previous trials have relied on multimodal brain imaging, whereas non-contrast CT is mostly used in clinical practice. Methods In a prospective multicentre, open-label, randomised trial, patients with acute ischaemic stroke due to large vessel occlusion in the anterior
-
Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial Lancet (IF 168.9) Pub Date : 2023-10-05 Sokoine Kivuyo, Josephine Birungi, Joseph Okebe, Duolao Wang, Kaushik Ramaiya, Samafilan Ainan, Faith Tumuhairwe, Simple Ouma, Ivan Namakoola, Anupam Garrib, Erik van Widenfelt, Gerald Mutungi, Gerard Abou Jaoude, Neha Batura, Joshua Musinguzi, Mina Nakawuka Ssali, Bernard Michael Etukoit, Kenneth Mugisha, Meshack Shimwela, Omary Said Ubuguyu, Jonathan Willitts
Background In sub-Saharan Africa, health-care provision for chronic conditions is fragmented. The aim of this study was to determine whether integrated management of HIV, diabetes, and hypertension led to improved rates of retention in care for people with diabetes or hypertension without adversely affecting rates of HIV viral suppression among people with HIV when compared to standard vertical care
-
Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study Lancet (IF 168.9) Pub Date : 2023-10-05 Deb Schrag, Tomasz M Beer, Charles H McDonnell, Lincoln Nadauld, Christina A Dilaveri, Robert Reid, Catherine R Marinac, Karen C Chung, Margarita Lopatin, Eric T Fung, Eric A Klein
Background Multicancer early detection (MCED) blood tests can detect a cancer signal from circulating cell-free DNA (cfDNA). PATHFINDER was a prospective cohort study investigating the feasibility of MCED testing for cancer screening. Methods In this prospective cohort study done in oncology and primary care outpatient clinics at seven US health networks, a convenience sample of adults aged 50 years
-
National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis Lancet (IF 168.9) Pub Date : 2023-10-05 Eric O Ohuma, Ann-Beth Moller, Ellen Bradley, Samuel Chakwera, Laith Hussain-Alkhateeb, Alexandra Lewin, Yemisrach B Okwaraji, Wahyu Retno Mahanani, Emily White Johansson, Tina Lavin, Diana Estevez Fernandez, Giovanna Gatica Domínguez, Ayesha de Costa, Jenny A Cresswell, Julia Krasevec, Joy E Lawn, Hannah Blencowe, Jennifer Requejo, Allisyn C Moran
Background Preterm birth is the leading cause of neonatal mortality and is associated with long-term physical, neurodevelopmental, and socioeconomic effects. This study updated national preterm birth rates and trends, plus novel estimates by gestational age subgroups, to inform progress towards global health goals and targets, and aimed to update country, regional, and global estimates of preterm birth
-
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial Lancet (IF 168.9) Pub Date : 2023-09-28 Catherine M Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J Kuter, Hanny Al-Samkari, James B Bussel, Marie Godar, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian Newland
Background Primary immune thrombocytopenia is an autoimmune disorder mediated partly by platelet autoantibodies, resulting in thrombocytopenia, bleeding, and constitutional symptoms. Efgartigimod, a first-in-class novel human IgG1 Fc fragment, binds the neonatal Fc receptor with high affinity and thus reduces serum IgG concentrations, including autoantibodies. The objective of this study was to evaluate
-
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial Lancet (IF 168.9) Pub Date : 2023-09-19 Akimichi Morita, Bruce Strober, A David Burden, Siew Eng Choon, Milan J Anadkat, Slaheddine Marrakchi, Tsen-Fang Tsai, Kenneth B Gordon, Diamant Thaçi, Min Zheng, Na Hu, Thomas Haeufel, Christian Thoma, Mark G Lebwohl
Background Spesolimab is an anti-interleukin-36 receptor monoclonal antibody approved to treat generalised pustular psoriasis (GPP) flares. We aimed to assess the efficacy and safety of spesolimab for GPP flare prevention. Methods This multicentre, randomised, placebo-controlled, phase 2b trial was done at 60 hospitals and clinics in 20 countries. Eligible study participants were aged between 12 and
-
Role of preoperative in-hospital delay on appendiceal perforation while awaiting appendicectomy (PERFECT): a Nordic, pragmatic, open-label, multicentre, non-inferiority, randomised controlled trial Lancet (IF 168.9) Pub Date : 2023-09-14 Karoliina Jalava, Ville Sallinen, Hanna Lampela, Hanna Malmi, Ingeborg Steinholt, Knut Magne Augestad, Ari Leppäniemi, Panu Mentula
Background Appendicectomy remains the standard treatment for appendicitis. No international consensus exists on the surgical urgency for acute uncomplicated appendicitis, and recommendations vary from surgery without delay to surgery within 24 h. Longer in-hospital delay has been thought to increase the risk of perforation and further morbidity. Therefore, we aimed to compare the rate of appendiceal
-
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial Lancet (IF 168.9) Pub Date : 2023-09-11 Zev A Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R Chandana, Christelle De La Fouchardière, Andrew Dean, Igor Kiss, Woo Jin Lee, Thorsten O Goetze, Eric Van Cutsem, A Scott Paulson, Tanios Bekaii-Saab, Shubham Pant, Richard A Hubner, Zhimin Xiao, Huanyu Chen, Fawzi Benzaghou, Eileen M O'Reilly
Background Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC). Methods NAPOLI 3 was a randomised, open-label, phase 3 study conducted at 187 community and academic sites
-
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial Lancet (IF 168.9) Pub Date : 2023-09-08 Arshad M Khanani, Sunil S Patel, Giovanni Staurenghi, Ramin Tadayoni, Carl J Danzig, David A Eichenbaum, Jason Hsu, Charles C Wykoff, Jeffrey S Heier, David R Lally, Jordi Monés, Jared S Nielsen, Veeral S Sheth, Peter K Kaiser, Julie Clark, Liansheng Zhu, Hersh Patel, Justin Tang, Dhaval Desai, Glenn J Jaffe, Edward Ysasaga
Background Geographic atrophy is an advanced form of dry age-related macular degeneration that can lead to irreversible vision loss and high burden of disease. We aimed to assess efficacy and safety of avacincaptad pegol 2 mg in reducing geographic atrophy lesion growth. Methods GATHER2 is a randomised, double-masked, sham-controlled, 24-month, phase 3 trial across 205 retina clinics, research hospitals
-
Home-based monitoring of ovulation to time frozen embryo transfers in the Netherlands (Antarctica-2): an open-label, nationwide, randomised, non-inferiority trial Lancet (IF 168.9) Pub Date : 2023-09-04 Tjitske Zaat, Jan-Peter de Bruin, Mariëtte Goddijn, Marchien van Baal, Sofie Benneheij, Monique Brandes, Frank Broekmans, Astrid Cantineau, Ben Cohlen, Jeroen van Disseldorp, Susanne Gielen, Eva Groenewoud, Arne van Heusden, Eugenie Kaaijk, Carolien Koks, Corry de Koning, Nicole Klijn, Paul van der Linden, Petra Manger, Lobke Moolenaar, Femke Mol
Background The growing field of assisted reproductive techniques, including frozen-thawed embryo transfer (FET), should lead the way to the best sustainable health care without compromising pregnancy chances. Correct timing of FET is crucial to allow implantation of the thawed embryo. Nowadays, timing based on hospital-controlled monitoring of ovulation in the natural cycle of a woman is the preferred
-
Outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves: a registry study Lancet (IF 168.9) Pub Date : 2023-08-31 Raj R Makkar, Samir Kapadia, Tarun Chakravarty, Robert J Cubeddu, Tsuyoshi Kaneko, Paul Mahoney, Dhairya Patel, Aakriti Gupta, Wen Cheng, Susheel Kodali, Deepak L Bhatt, Michael J Mack, Martin B Leon, Vinod H Thourani
Background With increasing numbers of patients undergoing transcatheter aortic valve replacement (TAVR), data on management of failed TAVR, including repeat TAVR procedure, are needed. The aim of this study was to assess the safety and efficacy of redo-TAVR in a national registry. Methods This study included all consecutive patients in the Society of Thoracic Surgeons/American College of Cardiology
-
Expedited transfer to a cardiac arrest centre for non-ST-elevation out-of-hospital cardiac arrest (ARREST): a UK prospective, multicentre, parallel, randomised clinical trial Lancet (IF 168.9) Pub Date : 2023-08-27 Tiffany Patterson, Gavin D Perkins, Alexander Perkins, Tim Clayton, Richard Evans, Matthew Dodd, Steven Robertson, Karen Wilson, Adam Mellett-Smith, Rachael T Fothergill, Paul McCrone, Miles Dalby, Philip MacCarthy, Sam Firoozi, Iqbal Malik, Roby Rakhit, Ajay Jain, Jerry P Nolan, Simon R Redwood, , Mamas Mamas
Background The International Liaison Committee on Resuscitation has called for a randomised trial of delivery to a cardiac arrest centre. We aimed to assess whether expedited delivery to a cardiac arrest centre compared with current standard of care following resuscitated cardiac arrest reduces deaths. Methods ARREST is a prospective, parallel, multicentre, open-label, randomised superiority trial
-
Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials Lancet (IF 168.9) Pub Date : 2023-08-26 Uwe Zeymer, Anne Freund, Matthias Hochadel, Petr Ostadal, Jan Belohlavek, Richard Rokyta, Steffen Massberg, Stefan Brunner, Enzo Lüsebrink, Marcus Flather, David Adlam, Kris Bogaerts, Amerjeet Banning, Manel Sabaté, Ibrahim Akin, Alexander Jobs, Steffen Schneider, Steffen Desch, Holger Thiele
Background Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used in patients with cardiogenic shock despite the lack of evidence from adequately powered randomised clinical trials. Three trials reported so far were underpowered to detect a survival benefit; we therefore conducted an individual patient-based meta-analysis to assess the effect of VA-ECMO on 30-day death rate
-
Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial Lancet (IF 168.9) Pub Date : 2023-08-25 David Conen, Michael Ke Wang, Ekaterine Popova, Matthew T V Chan, Giovanni Landoni, Juan P Cata, Cara Reimer, Sean R McLean, Sadeesh K Srinathan, Juan Carlos Trujillo Reyes, Ascension Martín Grande, Anna Gonzalez Tallada, Daniel I Sessler, Edith Fleischmann, Barbara Kabon, Luca Voltolini, Patrícia Cruz, Donna E Maziak, Laura Gutiérrez-Soriano, William F McIntyre, Jeremy S. Poppers
Background Higher levels of inflammatory biomarkers are associated with an increased risk of perioperative atrial fibrillation and myocardial injury after non-cardiac surgery (MINS). Colchicine is an anti-inflammatory drug that might reduce the incidence of these complications. Methods COP-AF was a randomised trial conducted at 45 sites in 11 countries. Patients aged 55 years or older and undergoing
-
Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: individual participant data meta-analysis of six randomised trials Lancet (IF 168.9) Pub Date : 2023-08-25 Charles B Majoie, Fabiano Cavalcante, Jan Gralla, Pengfei Yang, Johannes Kaesmacher, Kilian M Treurniet, Manon Kappelhof, Bernard Yan, Kentaro Suzuki, Yongwei Zhang, Fengli Li, Masafumi Morimoto, Lei Zhang, Zhongrong Miao, Leon A Rinkel, Jiacheng Huang, Toshiaki Otsuka, Shouchun Wang, Stephen Davis, Christophe Cognard, Margaux Lefebvre
Background Intravenous thrombolysis is recommended before endovascular treatment, but its value has been questioned in patients who are admitted directly to centres capable of endovascular treatment. Existing randomised controlled trials have indicated non-inferiority of endovascular treatment alone or have been statistically inconclusive. We formed the Improving Reperfusion Strategies in Acute Ischaemic
-
Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial Lancet (IF 168.9) Pub Date : 2023-08-24 Bruce L Wilkoff, Gerasimos Filippatos, Christophe Leclercq, Michael R Gold, Ahmad S Hersi, Kengo Kusano, Wilfried Mullens, G Michael Felker, Charan Kantipudi, Mikhael F El-Chami, Vidal Essebag, Bertrand Pierre, Francois Philippon, Francisco Perez-Gil, Eugene S Chung, Juan Sotomonte, Stanley Tung, Balbir Singh, Babak Bozorgnia, Satish Goel, David Birnie
Background Continuous automatic optimisation of cardiac resynchronisation therapy (CRT), stimulating only the left ventricle to fuse with intrinsic right bundle conduction (synchronised left ventricular stimulation), might offer better outcomes than conventional CRT in patients with heart failure, left bundle branch block, and normal atrioventricular conduction. This study aimed to compare clinical
-
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial Lancet (IF 168.9) Pub Date : 2023-08-23 Hope S Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal L Jhaveri, Rosemary Delaney, Theresa Valdez, Hao Wang, Monica Motwani, Oh Kyu Yoon, Wendy Verret, Sara M Tolaney
Background Sacituzumab govitecan demonstrated significant progression-free survival benefit over chemotherapy in the phase 3 TROPiCS-02 trial in patients with pretreated, endocrine-resistant hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ and HER2–) metastatic breast cancer with limited treatment options. Here, we report the protocol-specified final analysis of overall
-
Immune response after pig-to-human kidney xenotransplantation: a multimodal phenotyping study Lancet (IF 168.9) Pub Date : 2023-08-17 Alexandre Loupy, Valentin Goutaudier, Alessia Giarraputo, Fariza Mezine, Erwan Morgand, Blaise Robin, Karen Khalil, Sapna Mehta, Brendan Keating, Amy Dandro, Anaïs Certain, Pierre-Louis Tharaux, Navneet Narula, Renaud Tissier, Sébastien Giraud, Thierry Hauet, Harvey I Pass, Aurélie Sannier, Ming Wu, Adam Griesemer, Robert A Montgomery
Background Cross-species immunological incompatibilities have hampered pig-to-human xenotransplantation, but porcine genome engineering recently enabled the first successful experiments. However, little is known about the immune response after the transplantation of pig kidneys to human recipients. We aimed to precisely characterise the early immune responses to the xenotransplantation using a multimodal
-
Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study Lancet (IF 168.9) Pub Date : 2023-08-16 Dominique van Mil, Lyanne M Kieneker, Birgitte Evers-Roeten, Marc H M Thelen, Hanne de Vries, Marc H Hemmelder, Annemiek Dorgelo, Ronald W van Etten, Hiddo J L Heerspink, Ron T Gansevoort
Background Chronic kidney disease (CKD) has a rising global prevalence and is expected to become the fifth leading cause of death by 2030. Increased albuminuria defines the early stages of CKD and is among the strongest risk factors for progressive CKD and cardiovascular disease. The value of population screening for albuminuria to detect CKD in an early phase has yet to be studied. We aimed to evaluate
-
Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial Lancet (IF 168.9) Pub Date : 2023-08-16 Raymond Hang Wun Li, Sue Seen Tsing Lo, Kristina Gemzell-Danielsson, Carol Ho Yi Fong, Pak Chung Ho, Ernest Hung Yu Ng
Background Levonorgestrel, a standard drug for emergency contraception (EC), is not effective if administered post-ovulation. A cyclo-oxygenase inhibitor could contribute synergistic effects. We investigated whether a single 40 mg oral dose of piroxicam as co-treatment with levonorgestrel improved emergency contraceptive efficacy. Methods This was a randomised double-blind placebo-controlled trial
-
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial Lancet (IF 168.9) Pub Date : 2023-08-14 Richard Lafayette, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimir Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N Reich, Brad H Rovin, Jonathan Barratt
Background IgA nephropathy is a chronic immune-mediated kidney disease and a major cause of kidney failure worldwide. The gut mucosal immune system is implicated in its pathogenesis, and Nefecon is a novel, oral, targeted-release formulation of budesonide designed to act at the gut mucosal level. We present findings from the 2-year, phase 3 NefIgArd trial of Nefecon in patients with IgA nephropathy
-
Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study Lancet (IF 168.9) Pub Date : 2023-08-09 Miquel Serra-Burriel, Adrià Juanola, Feliu Serra-Burriel, Maja Thiele, Isabel Graupera, Elisa Pose, Guillem Pera, Ivica Grgurevic, Llorenç Caballeria, Salvatore Piano, Laurens van Kleef, Mathias Reichert, Dominique Roulot, Juan M Pericàs, Jörn M Schattenberg, Emmanuel A Tsochatztis, Indra Neil Guha, Montserrat Garcia-Retortillo, Rosario Hernández, Jordi Hoyo, Tracey Wildsmith
Background Liver cirrhosis is a major cause of death worldwide. Cirrhosis develops after a long asymptomatic period of fibrosis progression, with the diagnosis frequently occurring late, when major complications or cancer develop. Few reliable tools exist for timely identification of individuals at risk of cirrhosis to allow for early intervention. We aimed to develop a novel score to identify individuals
-
Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT): a pragmatic, superiority, open-label, randomised controlled trial Lancet (IF 168.9) Pub Date : 2023-08-10 Simon D Kyle, A Niroshan Siriwardena, Colin A Espie, Yaling Yang, Stavros Petrou, Emma Ogburn, Nargis Begum, Leonie F Maurer, Barbara Robinson, Caroline Gardner, Victoria Lee, Stephanie Armstrong, Julie Pattinson, Sam Mort, Eleanor Temple, Victoria Harris, Ly-Mee Yu, Peter Bower, Paul Aveyard
Background Insomnia is prevalent and distressing but access to the first-line treatment, cognitive behavioural therapy (CBT), is extremely limited. We aimed to assess the clinical and cost-effectiveness of sleep restriction therapy, a key component of CBT, which has the potential to be widely implemented. Methods We did a pragmatic, superiority, open-label, randomised controlled trial of sleep restriction
-
Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial Lancet (IF 168.9) Pub Date : 2023-08-08 Anurag Bhargava, Madhavi Bhargava, Ajay Meher, Andrea Benedetti, Banurekha Velayutham, G Sai Teja, Basilea Watson, Ganesh Barik, Rajeev Ranjan Pathak, Ranjit Prasad, Rakesh Dayal, Adarsh Kibballi Madhukeshwar, Vineet Chadha, Madhukar Pai, Rajendra Joshi, Dick Menzies, Soumya Swaminathan
Background In India, tuberculosis and undernutrition are syndemics with a high burden of tuberculosis coexisting with a high burden of undernutrition in patients and in the population. The aim of this study was to determine the effect of nutritional supplementation on tuberculosis incidence in household contacts of adults with microbiologically confirmed pulmonary tuberculosis. Methods In this field-based
-
Cause-specific mortality by county, race, and ethnicity in the USA, 2000–19: a systematic analysis of health disparities Lancet (IF 168.9) Pub Date : 2023-08-03
Background Large disparities in mortality exist across racial–ethnic groups and by location in the USA, but the extent to which racial–ethnic disparities vary by location, or how these patterns vary by cause of death, is not well understood. We aimed to estimate age-standardised mortality by racial–ethnic group, county, and cause of death and describe the intersection between racial–ethnic and place-based
-
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial Lancet (IF 168.9) Pub Date : 2023-07-28 Christopher W Ryan, Catherine M Tangen, Elisabeth I Heath, Mark N Stein, Maxwell V Meng, Ajjai S Alva, Sumanta K Pal, Igor Puzanov, Joseph I Clark, Toni K Choueiri, Neeraj Agarwal, Robert G Uzzo, Naomi B Haas, Timothy W Synold, Melissa Plets, Ulka N Vaishampayan, Brian M Shuch, Ian M Thompson, Primo N Lara
Background Patients undergoing resection of renal cell carcinoma are at risk of disease relapse. We evaluated the effectiveness of the mammalian target of rapamycin inhibitor everolimus administered after surgery. Methods In this randomised, double-blind, phase 3 trial, we enrolled adults with histologically confirmed renal cell carcinoma who had undergone a full surgical resection and were at intermediate-high
-
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet (IF 168.9) Pub Date : 2023-07-26 Patricia Pozo-Rosich, Jessica Ailani, Messoud Ashina, Peter J Goadsby, Richard B Lipton, Uwe Reuter, Hua Guo, Brittany Schwefel, Kaifeng Lu, Ramesh Boinpally, Rosa Miceli, Rosa De Abreu Ferreira, Emily McCusker, Sung Yun Yu, Lawrence Severt, Michelle Finnegan, Joel M Trugman
Background In this study, we aimed to evaluate the efficacy, safety, and tolerability of atogepant for the preventive treatment of chronic migraine. Methods We did this randomised, double-blind, placebo-controlled, phase 3 trial at 142 clinical research sites across the USA, the UK, Canada, China, Czech Republic, Denmark, France, Germany, Italy, Japan, South Korea, Poland, Russia, Spain, Sweden, and
-
The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review Lancet (IF 168.9) Pub Date : 2023-07-22 Laura N Broyles, Robert Luo, Debi Boeras, Lara Vojnov
Background The risk of sexual transmission of HIV from individuals with low-level HIV viraemia receiving antiretroviral therapy (ART) has important public health implications, especially in resource-limited settings that use alternatives to plasma-based viral load testing. This Article summarises the evidence related to sexual transmission of HIV at varying HIV viral load levels to inform messaging
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study Lancet (IF 168.9) Pub Date : 2023-07-24 Shukui Qin, Stephen L Chan, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, Gontran Verset
Background Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-angiogenic therapy alone in advanced solid tumours, but not in hepatocellular carcinoma. Therefore, a clinical study was conducted to compare the efficacy and safety of the anti-PD-1 antibody camrelizumab plus the VEGFR2-targeted
-
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial Lancet (IF 168.9) Pub Date : 2023-07-18 Joe Y Chang, Steven H Lin, Wenli Dong, Zhongxing Liao, Saumil J Gandhi, Carl M Gay, Jianjun Zhang, Stephen G Chun, Yasir Y Elamin, Frank V Fossella, George Blumenschein, Tina Cascone, Xiuning Le, Jenny V Pozadzides, Anne Tsao, Vivek Verma, James W Welsh, Aileen B Chen, Mehmet Altan, Reza J Mehran, John V Heymach
Background Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable early-stage non-small-cell lung cancer (NSCLC), but regional or distant relapses, or both, are common. Immunotherapy reduces recurrence and improves survival in people with stage III NSCLC after chemoradiotherapy, but its utility in stage I and II cases is unclear. We therefore conducted a randomised
-
Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial Lancet (IF 168.9) Pub Date : 2023-07-18 Frank R Lin, James R Pike, Marilyn S Albert, Michelle Arnold, Sheila Burgard, Theresa Chisolm, David Couper, Jennifer A Deal, Adele M Goman, Nancy W Glynn, Theresa Gmelin, Lisa Gravens-Mueller, Kathleen M Hayden, Alison R Huang, David Knopman, Christine M Mitchell, Thomas Mosley, James S Pankow, Nicholas S Reed, Victoria Sanchez, Josef Coresh
Background Hearing loss is associated with increased cognitive decline and incident dementia in older adults. We aimed to investigate whether a hearing intervention could reduce cognitive decline in cognitively healthy older adults with hearing loss. Methods The ACHIEVE study is a multicentre, parallel-group, unmasked, randomised controlled trial of adults aged 70–84 years with untreated hearing loss
-
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial Lancet (IF 168.9) Pub Date : 2023-07-11 Jürgen C Becker, Selma Ugurel, Ulrike Leiter, Friedegund Meier, Ralf Gutzmer, Sebastian Haferkamp, Lisa Zimmer, Elisabeth Livingstone, Thomas K Eigentler, Axel Hauschild, Felix Kiecker, Jessica C Hassel, Peter Mohr, Michael Fluck, Ioannis Thomas, Marlene Garzarolli, Imke Grimmelmann, Konstantin Drexler, Alexandra N Spillner, Sebastian Eckhardt, Bastian Schilling
Background Merkel cell carcinoma (MCC) is an immunogenic but aggressive skin cancer. Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 checkpoint inhibitors showed clinical benefit in advanced MCC. We aimed to assess efficacy and safety of adjuvant immune checkpoint inhibition in completely resected MCC (ie, a setting without an established systemic standard-of-care
-
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study Lancet (IF 168.9) Pub Date : 2023-07-06 Siow Ming Lee, Christian Schulz, Kumar Prabhash, Dariusz Kowalski, Aleksandra Szczesna, Baohui Han, Achim Rittmeyer, Toby Talbot, David Vicente, Raffaele Califano, Diego Cortinovis, Anh Tuan Le, Dingzhi Huang, Geoffrey Liu, Federico Cappuzzo, Jessica Reyes Contreras, Martin Reck, Ramon Palmero, Milena Perez Mak, Youyou Hu, Solange Peters
Background Despite immunotherapy advancements for patients with advanced or metastatic non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 and a median age of 65 years or younger. We aimed to compare the efficacy and safety of first-line atezolizumab monotherapy with single-agent chemotherapy
-
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial Lancet (IF 168.9) Pub Date : 2023-07-06 Athimalaipet V Ramanan, Pierre Quartier, Nami Okamoto, Ivan Foeldvari, Alberto Spindler, Šárka Fingerhutová, Jordi Antón, Zhongkai Wang, Gabriella Meszaros, Joana Araújo, Ran Liao, Stuart Keller, Hermine I Brunner, Nicolino Ruperto
Background Juvenile idiopathic arthritis can be refractory to some or all treatment regimens, therefore new medications are needed to treat this population. This trial assessed the efficacy and safety of baricitinib, an oral Janus kinase 1/2-selective inhibitor, versus placebo in patients with juvenile idiopathic arthritis. Methods This phase 3, randomised, double-blind, placebo-controlled, withdrawal
-
Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham-controlled, multicentre trial Lancet (IF 168.9) Pub Date : 2023-07-03 Gerrit Burkhardt, Ulrike Kumpf, Alexander Crispin, Stephan Goerigk, Elisabeth Andre, Christian Plewnia, Bettina Brendel, Andreas Fallgatter, Berthold Langguth, Mohamed Abdelnaim, Tobias Hebel, Claus Normann, Lukas Frase, Peter Zwanzger, Julia Diemer, Thomas Kammer, Carlos Schönfeldt-Lecuona, Daniel Kamp, Malek Bajbouj, Nora Behler, Frank Padberg
Background Transcranial direct current stimulation (tDCS) has been proposed as a feasible treatment for major depressive disorder (MDD). However, meta-analytic evidence is heterogenous and data from multicentre trials are scarce. We aimed to assess the efficacy of tDCS versus sham stimulation as an additional treatment to a stable dose of selective serotonin reuptake inhibitors (SSRIs) in adults with
-
The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019 Lancet (IF 168.9) Pub Date : 2023-06-29
Background Communicable disease control has long been a focus of global health policy. There have been substantial reductions in the burden and mortality of communicable diseases among children younger than 5 years, but we know less about this burden in older children and adolescents, and it is unclear whether current programmes and policies remain aligned with targets for intervention. This knowledge
-
Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report Lancet (IF 168.9) Pub Date : 2023-06-29 Muhammad M Mohiuddin, Avneesh K Singh, Linda Scobie, Corbin E Goerlich, Alison Grazioli, Kapil Saharia, Claire Crossan, Allen Burke, Cinthia Drachenberg, Cihan Oguz, Tianshu Zhang, Billeta Lewis, Alena Hershfeld, Faith Sentz, Ivan Tatarov, Sarah Mudd, Gheorghe Braileanu, Kathryn Rice, John F Paolini, Kent Bondensgaard, Bartley P Griffith
Background A genetically engineered pig cardiac xenotransplantation was done on Jan 7, 2022, in a non-ambulatory male patient, aged 57 years, with end-stage heart failure, and on veno-arterial extracorporeal membrane oxygenation support, who was ineligible for an allograft. This report details our current understanding of factors important to the xenotransplantation outcome. Methods Physiological and
-
Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial Lancet (IF 168.9) Pub Date : 2023-06-29 Alice Beardmore-Gray, Nicola Vousden, Paul T Seed, Bellington Vwalika, Sebastian Chinkoyo, Victor Sichone, Alexander B Kawimbe, Umesh Charantimath, Geetanjali Katageri, Mrutyunjaya B Bellad, Laxmikant Lokare, Kasturi Donimath, Shailaja Bidri, Shivaprasad Goudar, Jane Sandall, Lucy C Chappell, Andrew H Shennan
Background Pre-eclampsia is a leading cause of maternal and perinatal mortality. Evidence regarding interventions in a low-income or middle-income setting is scarce. We aimed to evaluate whether planned delivery between 34+ 0 and 36+ 6 weeks’ gestation can reduce maternal mortality and morbidity without increasing perinatal complications in India and Zambia. Methods In this parallel-group, multicentre
-
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study Lancet (IF 168.9) Pub Date : 2023-06-24 Juan P Frias, Stanley Hsia, Sarah Eyde, Rong Liu, Xiaosu Ma, Manige Konig, Christof Kazda, Kieren J Mather, Axel Haupt, Edward Pratt, Deborah Robins
Background Orforglipron, an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist, is in development for type 2 diabetes and obesity. We assessed the efficacy and safety of orforglipron versus placebo or dulaglutide in participants with type 2 diabetes. Methods In this 26-week, phase 2, double-blind, randomised, multicentre study, participants were recruited from 45 centres (private clinics
-
Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial Lancet (IF 168.9) Pub Date : 2023-06-28 Caitlin M P Jones, Richard O Day, Bart W Koes, Jane Latimer, Chris G Maher, Andrew J McLachlan, Laurent Billot, Sana Shan, Chung-Wei Christine Lin
Background Opioid analgesics are commonly used for acute low back pain and neck pain, but supporting efficacy data are scarce. We aimed to investigate the efficacy and safety of a judicious short course of an opioid analgesic for acute low back pain and neck pain. Methods OPAL was a triple-blinded, placebo-controlled randomised trial that recruited adults (aged ≥18 years) presenting to one of 157 primary